256 related articles for article (PubMed ID: 34590610)
1. Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases.
Chan D; Kaplan J; Gordon G; Desai J
Curr Oncol; 2021 Sep; 28(5):3659-3667. PubMed ID: 34590610
[TBL] [Abstract][Full Text] [Related]
2. Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Kummar S; O'Sullivan Coyne G; Do KT; Turkbey B; Meltzer PS; Polley E; Choyke PL; Meehan R; Vilimas R; Horneffer Y; Juwara L; Lih A; Choudhary A; Mitchell SA; Helman LJ; Doroshow JH; Chen AP
J Clin Oncol; 2017 May; 35(14):1561-1569. PubMed ID: 28350521
[TBL] [Abstract][Full Text] [Related]
3. The Notch signaling pathway in desmoid tumor: Recent advances and the therapeutic prospects.
Zheng C; Huang J; Xu G; Li W; Weng X; Zhang S
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166907. PubMed ID: 37793461
[TBL] [Abstract][Full Text] [Related]
4. Current management and recent progress in desmoid tumors.
Zhou MY; Bui NQ; Charville GW; Ghanouni P; Ganjoo KN
Cancer Treat Res Commun; 2022; 31():100562. PubMed ID: 35460976
[TBL] [Abstract][Full Text] [Related]
5. Multifocal occurrence of extra-abdominal desmoid type fibromatosis - A rare manifestation. A clinicopathological study of 6 sporadic cases and 1 hereditary case.
Bekers EM; van Broekhoven DLM; van Dalen T; Bonenkamp JJ; van der Geest ICM; de Rooy JWJ; van Gorp JM; Creytens DH; de Leng WWJ; Scheijen B; Eijkelenboom A; Flucke U
Ann Diagn Pathol; 2018 Aug; 35():38-41. PubMed ID: 29705714
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition.
Federman N
NPJ Precis Oncol; 2022 Sep; 6(1):62. PubMed ID: 36068332
[TBL] [Abstract][Full Text] [Related]
7. AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling.
Ferrarotto R; Mishra V; Herz E; Yaacov A; Solomon O; Rauch R; Mondshine A; Motin M; Leibovich-Rivkin T; Davis M; Kaye J; Weber CR; Shen L; Pearson AT; Rosenberg AJ; Chen X; Singh A; Aster JC; Agrawal N; Izumchenko E
Cell Death Dis; 2022 Aug; 13(8):678. PubMed ID: 35931701
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.
McLean TD; Duchi S; Di Bella C
Target Oncol; 2022 May; 17(3):223-252. PubMed ID: 35446005
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases.
Takahashi T; Prensner JR; Robson CD; Janeway KA; Weigel BJ
Pediatr Blood Cancer; 2020 Oct; 67(10):e28636. PubMed ID: 32762028
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.
Villalobos VM; Hall F; Jimeno A; Gore L; Kern K; Cesari R; Huang B; Schowinsky JT; Blatchford PJ; Hoffner B; Elias A; Messersmith W
Ann Surg Oncol; 2018 Mar; 25(3):768-775. PubMed ID: 28887726
[TBL] [Abstract][Full Text] [Related]
11. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
[TBL] [Abstract][Full Text] [Related]
12. Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives.
Ibrahim R; Assi T; Khoury R; Ngo C; Faron M; Verret B; Lévy A; Honoré C; Hénon C; Le Péchoux C; Bahleda R; Le Cesne A
Cancer Treat Rev; 2024 Feb; 123():102675. PubMed ID: 38159438
[TBL] [Abstract][Full Text] [Related]
13. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors.
Shang H; Braggio D; Lee YJ; Al Sannaa GA; Creighton CJ; Bolshakov S; Lazar AJ; Lev D; Pollock RE
Cancer; 2015 Nov; 121(22):4088-96. PubMed ID: 26349011
[TBL] [Abstract][Full Text] [Related]
15. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
[TBL] [Abstract][Full Text] [Related]
16. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
Gounder M; Ratan R; Alcindor T; Schöffski P; van der Graaf WT; Wilky BA; Riedel RF; Lim A; Smith LM; Moody S; Attia S; Chawla S; D'Amato G; Federman N; Merriam P; Van Tine BA; Vincenzi B; Benson C; Bui NQ; Chugh R; Tinoco G; Charlson J; Dileo P; Hartner L; Lapeire L; Mazzeo F; Palmerini E; Reichardt P; Stacchiotti S; Bailey HH; Burgess MA; Cote GM; Davis LE; Deshpande H; Gelderblom H; Grignani G; Loggers E; Philip T; Pressey JG; Kummar S; Kasper B
N Engl J Med; 2023 Mar; 388(10):898-912. PubMed ID: 36884323
[TBL] [Abstract][Full Text] [Related]
17. Desmoid tumor: a disease opportune for molecular insights.
Kotiligam D; Lazar AJ; Pollock RE; Lev D
Histol Histopathol; 2008 Jan; 23(1):117-26. PubMed ID: 17952864
[TBL] [Abstract][Full Text] [Related]
18. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.
Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
[TBL] [Abstract][Full Text] [Related]
20. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
Norkowski E; Masliah-Planchon J; Le Guellec S; Trassard M; Courrèges JB; Charron-Barra C; Terrier P; Bonvalot S; Coindre JM; Laé M
Am J Surg Pathol; 2020 Sep; 44(9):1266-1273. PubMed ID: 32590455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]